Clinical Trials Logo

Filter by:
NCT ID: NCT06208748 Not yet recruiting - Clinical trials for Gastrointestinal Stromal Tumors

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.

NCT ID: NCT06208722 Recruiting - Autism Clinical Trials

Testing a Mobile App to Improve Toothbrushing Skills and Habits in Teens With Autism

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

The goal of this proposed trial will modify an existing toothbrushing app for teens with autism and compare toothbrushing outcomes with a control app. We have 2 specific aims: - During the 2-year UG3 phase, we will use the Discover, Design+Build, and Test Framework to modify our existing app and pilot the intervention. - During the 4-year UH3 phase, we will recruit 270 pre-adolescents and teens with autism ages 10 to 17 years, randomize participants to one of two arms, and compare outcomes. Participants will asked to use the app, complete surveys on REDCap, participate in feedback interviews and focus groups. Behavior change in the experimental group will be compared with that in the control group.

NCT ID: NCT06208631 Recruiting - Clinical trials for Osteoarthritis, Knee

Effects of Movement Retraining on Knee Loading in Individuals With Knee Osteoarthritis

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

This study investigates how well individuals with knee osteoarthritis can learn to alter their calf muscle activation using haptic biofeedback while walking and evaluates how these changes affect knee loading. Prior research has utilized musculoskeletal simulations to determine that reducing the activation of one of the calf muscles, the gastrocnemius, can have a large impact on reducing knee loading. However, this has not been tested in individuals with knee osteoarthritis. In this study, participants will be trained to alter the activation of their gastrocnemius muscle, by receiving haptic feedback after each step. The feedback will indicate how the participant changed their muscle activation relative to baseline. Participants will train for up to three sessions, with 30 minutes of walking with feedback in each session. If a participant can learn to adjust their muscle activation in the first training session, they will be able to complete the second training session. An exploratory third session may be conducted to investigate changes in knee loading while using the new walking strategy during over-ground walking. The movement data collected during the training sessions will be used as inputs to computer simulations of the musculoskeletal system to determine if walking with the new muscle activation strategy reduces knee loading.

NCT ID: NCT06208605 Recruiting - Eating Disorders Clinical Trials

Innovations in Personalizing Treatment Study

T-NIPT-ED
Start date: January 21, 2024
Phase: N/A
Study type: Interventional

Eating disorders (EDs) are serious mental illness: someone dies of an ED every 52 minutes. EDs are highly related to a host of negative outcomes, including public health and individual disease burden, medical and psychological comorbidities, and social determinants of health (SDOH). Treatment response for EDs are suboptimal; there are no evidence-based treatment for adults with anorexia nervosa (AN) or Other Specified Feeding or Eating Disorder (OSFED) and only 50% of adults respond to current evidence based treatments. There are no precision treatments, nor any treatments that consider social context, in existence. Personalized treatments for EDs, that consider social contexts, are urgently needed to improve treatment response and minimize the suffering associated with these illnesses. The investigators' overall goal, extending upon their past work, is to create a treatment personalized based on idiographic (or one person) models (termed Transdiagnostic Network Informed Personalized Treatment for EDs; T-NIPT-ED). The investigators will carry out a two-phase study to systematically characterize individual mechanisms of treatment (Phase I: N=900) and then test the efficacy of each treatment module (Phase II: N=240 drawn from Phase I) compared to the current gold-standard treatment (Cognitive Behavioral Therapy Enhanced: CBT-E). The study goals are to (1) characterize the prevalence of T-NIPT-ED precision treatment mechanisms and medical and psychological comorbidities (e.g., obesity; depression), individual disease burden (e.g., disability), SDOH (e.g., food insecurity), and public health outcomes (e.g., service utilization) specific to these mechanisms, (2) identify if personalized target mechanisms improve when matched to evidence-based treatment modules of T-NIPT-ED and (3) test if change in T-NIPT-ED is associated with improved outcomes (vs CBT-E), including ED outcomes, comorbidities, disease burden, and public health outcomes and if these outcomes are moderated by SDOH. These goals will ultimately lead to the very first precision treatment for ED and can be extended to additional psychiatric illnesses. The proposed research uses highly innovative methods; intensive longitudinal data collected with mobile technology is combined with state-of-the art idiographic modeling methods to deliver a virtual, personalized treatment. This proposal integrates assessment of broad (e.g., SDOH; public health burden) and specific (e.g., ED symptoms) outcomes, to ensure that social context can be integrated into personalization. The proposed research has high clinical impact. Ultimately, this proposal will lead directly to the creation and dissemination of an evidence-based individually-personalized treatment for EDs, as well as will serve as an exemplar for precision treatment development across the entire field of psychiatry.

NCT ID: NCT06208566 Completed - Clinical trials for Well-Being, Psychological

A Bot-based Self-help Program (WELL)

WELL
Start date: July 4, 2022
Phase: N/A
Study type: Interventional

In the current project, the effectiveness of a new bot-based universal prevention program aimed at improving well-being will be developed and tested. This prevention program includes a variety of modules that target common areas related to well-being including interpersonal relationships, emotional regulation, beliefs and behaviors, problem-solving, sleep hygiene, goal setting, personal growth, and healthy habits.

NCT ID: NCT06208514 Recruiting - Fibromyalgia Clinical Trials

Brief Pain Exposure Therapy for Fibromyalgia (BPET) Study

BPET
Start date: March 4, 2024
Phase: N/A
Study type: Interventional

This study is intended to test whether a brief Zoom-based behavioral treatment can help adults with fibromyalgia learn effective strategies for reducing pain, disability and other problems that can come with fibromyalgia (such as depression or anxiety).

NCT ID: NCT06208423 Recruiting - Clinical trials for Clinical Decision-making

Physician Reasoning on Management Cases With Large Language Models

Start date: December 28, 2023
Phase: N/A
Study type: Interventional

This study will evaluate the effect of providing access to GPT-4, a large language model, compared to traditional management decision support tools on performance on case-based management reasoning tasks.

NCT ID: NCT06208306 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

AERIFY-4
Start date: January 11, 2024
Phase: Phase 3
Study type: Interventional

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments. The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819. Study details include: - The study duration will be up to 72 weeks - The treatment duration will be up to 52 weeks - A follow-up period of 20 weeks will be conducted - The number of on-site visits will be 7 and the number of phone contacts will be 5

NCT ID: NCT06208202 Recruiting - Exposure Clinical Trials

Perceptions of E-Cigarettes and Synthetic Cooling Agents, The ICE Study

ICE
Start date: May 8, 2024
Phase: N/A
Study type: Interventional

This study evaluates how synthetic cooling additives like WS-3 and WS-23 impact e-cigarette perceptions, use behavior, and toxicant exposure.

NCT ID: NCT06208189 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Is the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood Glucose

Start date: May 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the degree of effort during a resistance exercise session on blood glucose levels in individuals with prediabetes or type 2 diabetes mellitus. The main questions it aims to answer are: - Do individuals with prediabetes or type 2 diabetes mellitus need to perform resistance exercise with a high degree of effort for their blood glucose to improve? - How do they feel (their enjoyment, discomfort) after the sessions with different degrees of effort? Participants will perform 3 situations separated by at least 4 days, after being familiarized with all exercises and procedures: - One control day, when they will not exercise; - A high-effort resistance exercise session; - A low-effort resistance exercise session Researchers will measure blood glucose levels and psychological responses after these situations to see if the effort was important for the improvement of their blood glucose and how effort affected the way they felt after each situation.